Sarepta Therapeutics (NASDAQ:SRPT) Now Covered by Sanford C. Bernstein

Equities researchers at Sanford C. Bernstein began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “market perform” rating and a $13.00 price target on the biotechnology company’s stock. Sanford C. Bernstein’s target price would suggest a potential downside of 22.39% from the company’s previous close.

Other research analysts have also issued reports about the company. Wolfe Research initiated coverage on Sarepta Therapeutics in a research report on Tuesday, June 17th. They issued a “peer perform” rating on the stock. BMO Capital Markets reaffirmed a “market perform” rating and issued a $50.00 target price (down from $70.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. The Goldman Sachs Group lowered Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating and set a $29.00 target price on the stock. in a research report on Tuesday, June 17th. Cantor Fitzgerald reissued a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, June 16th. Finally, William Blair reissued a “market perform” rating on shares of Sarepta Therapeutics in a report on Thursday, July 17th. Six research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $49.12.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock opened at $16.75 on Tuesday. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $145.00. The stock’s 50-day moving average is $24.69 and its two-hundred day moving average is $62.20. The firm has a market cap of $1.65 billion, a P/E ratio of -6.23 and a beta of 0.45.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the company earned $0.73 earnings per share. The business’s revenue for the quarter was up 80.2% on a year-over-year basis. Analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of SRPT. Capital International Investors increased its holdings in Sarepta Therapeutics by 38.9% during the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares in the last quarter. Norges Bank acquired a new stake in Sarepta Therapeutics during the 4th quarter valued at $126,315,000. Aberdeen Group plc increased its holdings in Sarepta Therapeutics by 91.1% during the 2nd quarter. Aberdeen Group plc now owns 1,242,404 shares of the biotechnology company’s stock valued at $21,500,000 after purchasing an additional 592,125 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Sarepta Therapeutics by 438.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 712,581 shares of the biotechnology company’s stock valued at $45,477,000 after purchasing an additional 580,123 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock valued at $168,907,000 after purchasing an additional 577,848 shares in the last quarter. 86.68% of the stock is owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.